Ventricular arrhythmias

Preview

The decision to initiate long-term treatment of ventricular arrhythmias has always been difficult because of the substantial morbidity produced by many drugs and the potential for inducing proarrhythmia. Five recently introduced antiarrhythmic agents promise to enhance the physician's chances of prescribing effective therapy. In this article, the authors review the pharmacokinetic properties and efficacy of these newer agents and offer a clinical perspective on their use.